#ORGO hashtag - Bluesky

Pomerantz Law Firm Probes Organogenesis Holdings Inc. Investor Claims Amid Falling Stock Prices Pomerantz Law Firm is looking into potential investor claims against Organogenesis Holdings Inc. following a significant stock price drop due to recent regulatory announcements.

2 months ago

Pomerantz Law Firm Probes Organogenesis Holdings Inc. Investor Claims Amid Falling Stock Prices #United_States #New_York #Pomerantz_Law_Firm #Organogenesis_Holdings #ORGO

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

2 months ago

Leading Indicators, Tuesday January 6, 2026 – Crystal Equity Research

Small-cap stocks in new downtrend according to average directional index, Tue Jan 6th - #SLND #ORGO #MSEX #LDAM #HSTM #GBTH #CRSR #YEXT #VYX #LFT - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Market Wire News

@marketwirenews.com

3 months ago

JUST IN: ( NASDAQ: #ORGO ) Buy Recommendation Issued On ORGO By BTIG

0 0 0 0

Organogenesis Announces Initiation of Biologics License Application for ReNu® Organogenesis (Nasdaq: ORGO) has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee arthritis.Initial modules were submitted under rolling review with final modules expected in the first half of 2026. Company executives said ReNu, if approved, would be the first non-surgical biologic therapy for knee osteoarthritis across all patients, including the most severe. Knee osteoarthritis is estimated to affect 31.1 million Americans, rising to 34.4 million by 2027, with end-stage management typically a total knee replacement.

3 months ago

#ORGO Organogenesis Announces Initiation of Biologics License Application for ReNu®

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain Organogenesis (Nasdaq: ORGO) announced a successful Type-B meeting with the FDA and confirmation to initiate a rolling BLA submission for ReNu planned before the end of December 2025. The company said ReNu's clinical program—two large Phase 3 randomized controlled trials, a separate 200-patient RCT, extensive commercial history, and RMAT designation—was considered appropriate for BLA submission. Management stated that, if approved, ReNu could address a significant unmet need in knee osteoarthritis, a condition affecting an estimated 31.1 million Americans, projected to reach 34.4 million by 2027.

3 months ago

#ORGO Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

AI動作解析アプリ「MYoACT」が無制限プランを特別価格で提供開始！ AI動作解析アプリ「MYoACT」が、ユーザーの声に応えて無制限プランの特別キャンペーンを実施中。クレジットの心配なしで分析できるチャンス！

4 months ago

AI動作解析アプリ「MYoACT」が無制限プランを特別価格で提供開始！ #北海道 #札幌市 #ORGO #AI解析 #MYoACT

AI動作解析アプリ「MYoACT」が、ユーザーの声に応えて無制限プランの特別キャンペーンを実施中。クレジットの心配なしで分析できるチャンス！

0 0 0 0

4 months ago

#ORGO Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

Organogenesis Applauds CMS’s Significant Step In Payment Reform Organogenesis (Nasdaq: ORGO) applauded CMS’s finalization of payment reform for skin substitutes/CTPs under the CY 2026 Physician Fee Schedule announced Nov. 3, 2025.The company highlighted that CMS finalized FDA classifications and a per centimeter-square payment methodology for both physician office and hospital outpatient settings, and said CMS recognized the clinical differentiation of PMA products, which the company believes will increase access and support higher payment and expanded access for PMA technologies. Organogenesis reiterated its multi-decade leadership and said its evidence-based portfolio positions it well for the skin substitutes market in 2026 and beyond.The release contains forward-looking statements and cautions that actual outcomes are subject to risks and uncertainties described in the company’s SEC filings.

4 months ago

#ORGO Organogenesis Applauds CMS’s Significant Step In Payment Reform

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

Pomerantz Law Firm Investigates Potential Securities Fraud by Organogenesis Holdings Inc. Pomerantz Law Firm is probing potential securities fraud claims against Organogenesis Holdings Inc. after the company's pivotal trial failed to meet expectations.

5 months ago

Pomerantz Law Firm Investigates Potential Securities Fraud by Organogenesis Holdings Inc. #United_States #New_York #Pomerantz_Law_Firm #Organogenesis_Holdings #ORGO

0 0 0 0

Investors on Alert as Pomerantz Law Firm Probes Organogenesis Holdings for Possible Securities Fraud Pomerantz LLP is investigating securities fraud claims on behalf of Organogenesis Holdings investors following disappointing trial results that impacted stock prices significantly.

5 months ago

Investors on Alert as Pomerantz Law Firm Probes Organogenesis Holdings for Possible Securities Fraud #United_States #New_York #Pomerantz #ORGO #Organogenesis

0 0 0 0

Pomerantz Law Firm Investigates Securities Fraud Claims Against Organogenesis Holdings Inc. Pomerantz Law Firm is probing claims of securities fraud involving Organogenesis Holdings Inc. following disappointing trial results.

5 months ago

Pomerantz Law Firm Investigates Securities Fraud Claims Against Organogenesis Holdings Inc. #USA #New_York #Pomerantz_Law #Organogenesis_Holdings #ORGO

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

Original post on benzinga.com

Why Is Organogenesis Stock Trading Lower Friday? Organogenesis Holdings Inc. (NASDAQ: ORGO ) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cry...

#Biotech #News #ORGO #Penny #Stocks #why #it's #moving […]

[Original post on benzinga.com]

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

12 Health Care Stocks Moving In Friday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF), Clearside Biomedical (NASDAQ:CLSD) Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF ) stock increased by 71.8% to $5.86 during Friday's pre-market session. The compan...

#BIAF #BZI-TFM #CLSD #CRNX #DRIO #GUTS #MDCX #NLSP #ORGO #Penny #Stocks

Origin | Interest | Match

0 0 0 0

Organogenesis Provides Update on Second Phase 3 ReNu® Study Organogenesis (NASDAQ: ORGO) announced that its second Phase 3 trial for ReNu®, a treatment for knee osteoarthritis (OA), did not meet its primary endpoint despite showing improved pain reduction. The trial demonstrated a numerical improvement of -0.51 favoring ReNu (p=0.0393) compared to saline, falling short of the p=0.023 target threshold.Key highlights include baseline pain reduction of -6.9 at six months in the second Phase 3 study, improving from -6.0 in the first Phase 3 study. The company maintains confidence in ReNu's potential and plans to request a pre-BLA meeting with the FDA by end of October to discuss submission pathway, leveraging combined efficacy analysis from both Phase 3 studies.ReNu has been studied in three large RCTs with over 1,300 patients and has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation.

6 months ago

#ORGO Organogenesis Provides Update on Second Phase 3 ReNu® Study

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

Doodles in the Membrane

@doodlesmembrane.bsky.social

6 months ago

Hydrohalogenation Reaction Animation:
Covering the reaction of HBr with 3-methylbutene

This reaction includes a carbocation rearrangment.

#chemistry #ochem #orgo

0 0 0 0

はちまとニュース＠相互フォロー100%

@beemato.bsky.social

7 months ago

AI動作解析アプリMYoACTが抽選枠を増枠！年間プランプレゼントキャンペーン開催 AI動作解析アプリMYoACTがキャンペーンを拡大。抽選枠を増やし、業界別に年間プランを最大15社に無料プレゼントします！

AI動作解析アプリMYoACTが抽選枠を増枠！年間プランプレゼントキャンペーン開催 #AI動作解析 #MYoACT #ORGO

AI動作解析アプリMYoACTがキャンペーンを拡大。抽選枠を増やし、業界別に年間プランを最大15社に無料プレゼントします！

0 0 0 0

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results Organogenesis Holdings (NASDAQ: ORGO) reported Q2 2025 financial results showing a decline in performance. The company posted net product revenue of $100.8 million, down 23% from $130.2 million in Q2 2024. The Advanced Wound Care segment saw a 25% decrease to $92.7 million, while Surgical & Sports Medicine revenue increased 16% to $8.1 million.The company reported a net loss of $9.4 million ($0.10 per share), an improvement from a $17.0 million loss in Q2 2024. Adjusted EBITDA turned negative at $(3.6) million, compared to positive $15.6 million in the prior year. The company maintained a strong balance sheet with $73.7 million in cash and no debt.For full-year 2025, Organogenesis updated guidance, projecting revenue between $480-$510 million, representing flat to 6% growth, with net income ranging from $(6.4) million to $16.4 million.

7 months ago

#ORGO Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

AI動作解析アプリ「MYoACT」の正式リリースとその全貌 AI動作解析アプリ「MYoACT」が正式にリリースされました。スマホで簡単に動作分析が可能で、医療やスポーツでの活用が期待されています。

8 months ago

AI動作解析アプリ「MYoACT」の正式リリースとその全貌 #北海道 #札幌市 #ORGO #MYoACT #AI動作解析

AI動作解析アプリ「MYoACT」が正式にリリースされました。スマホで簡単に動作分析が可能で、医療やスポーツでの活用が期待されています。

0 0 0 0

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation Organogenesis (Nasdaq: ORGO), a regenerative medicine company, has expressed support for the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes in CY 2026. The proposal introduces a per centimeter square payment system based on FDA classification across both physician office and hospital outpatient settings.CEO Gary S. Gillheeney highlighted that the new structure aims to reduce system abuse and Medicare spending while ensuring consistent payment across care sites. The proposal notably recognizes PMA products' clinical differentiation and seeks to expand access to innovative wound healing technologies that help reduce amputations and complications.

8 months ago

#ORGO Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

9 months ago

運動習慣が姿勢に及ぼす影響とは？最新調査レポート #北海道 #札幌市 #ePose #ORGO #骨格

株式会社ORGOの調査で、運動習慣が姿勢に与える影響について詳しく解説します。年代別のデータも必見。

1 0 0 0

整骨院の問診満足度、17%が不満を実感 - AI活用で改善目指す 整骨院・整体院の問診に対し、17%の人が不満を抱える結果に。株式会社ORGOが実施した調査から見える問題点と、AIアプリの活用とは。

10 months ago

整骨院の問診満足度、17%が不満を実感 - AI活用で改善目指す #北海道 #札幌市 #整骨院 #ORGO #AI姿勢分析

整骨院・整体院の問診に対し、17%の人が不満を抱える結果に。株式会社ORGOが実施した調査から見える問題点と、AIアプリの活用とは。

1 0 0 0

整骨院・整体院のサービス満足度調査から見えてきた現状と課題 整骨院や整体院における担当スタッフの能力差についての調査結果を発表。多くの利用者が感じる不満とは？

10 months ago

整骨院・整体院のサービス満足度調査から見えてきた現状と課題 #北海道 #札幌市 #整骨院 #ORGO #AI姿勢分析

整骨院や整体院における担当スタッフの能力差についての調査結果を発表。多くの利用者が感じる不満とは？

1 0 0 0

整骨院・整体院に関する満足度調査、3人に1人が未改善の体験 整骨院や整体院で症状が改善されなかったと感じる人が多いことが明らかに。株式会社ORGOの調査結果を詳しく解説します。

10 months ago

整骨院・整体院に関する満足度調査、3人に1人が未改善の体験 #北海道 #札幌市 #整体院 #整骨院 #ORGO

整骨院や整体院で症状が改善されなかったと感じる人が多いことが明らかに。株式会社ORGOの調査結果を詳しく解説します。

1 0 0 0

姿勢データが改善意欲を促進する傾向を調査で確認 株式会社ORGOが実施した調査で、姿勢データが改善意欲を引き出すことが明らかに。年代や性別による満足度の傾向も注目。

10 months ago

姿勢データが改善意欲を促進する傾向を調査で確認 #北海道 #札幌市 #ePose #ORGO #姿勢改善

株式会社ORGOが実施した調査で、姿勢データが改善意欲を引き出すことが明らかに。年代や性別による満足度の傾向も注目。

1 0 0 0

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results Organogenesis Holdings Inc. (NASDAQ: ORGO) reported challenging Q1 2025 financial results with net revenue of $86.7M, down 21% from $110.0M in Q1 2024. The company saw a significant decline in Advanced Wound Care revenue (-23% to $79.9M), partially offset by growth in Surgical & Sports Medicine revenue (+11% to $6.8M). Net loss widened to $18.8M compared to $2.1M loss in Q1 2024. Despite market challenges, ORGO maintains its 2025 revenue guidance of $480-535M. The company has a strong balance sheet with $110.5M in cash and no debt. Management highlighted progress on ReNu development, with BLA submission expected by end of 2025. Operating expenses increased 5% to $89.7M, including a $6.6M write-down expense.

10 months ago

#ORGO Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ORGO/organogenesis-...

0 0 0 0

WorkentinChem 🇨🇦🍁

@workentinchem.bsky.social

11 months ago

This is my type of #orgo

2 1 0 0